Cite

HARVARD Citation

    Cui, Y. et al. (n.d.). Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects. European heart journal. p. . [Online]. 
  
Back to record